SCHEMBL5758628

SCHEMBL5758628

[c]1nc2c(OCc3nccs3)cccc2s1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.33
KDM1A O60341 1/20 0.33
MAOB P27338 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
SLC6A3 Q01959 1/20 0.33
BDKRB2 P30411 1/20 0.32
NPC1 O15118 4/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
RAB9A P51151 3/20 0.32
HPGD P15428 2/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 4/20 0.32
PKM P14618 2/20 0.32
HSD17B10 Q99714 1/20 0.32
CHRM2 P08172 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756170 0.80 NPC1 (0.36) ALDH1A1NPC1SMN1; SMN2RAB9AHPGD
SCHEMBL5758606 0.80 HTT (0.41) ALDH1A1GABRA1GABRG2GABRB3GABRA5
SCHEMBL557732 0.78 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2HPGDTP53MAPT
SCHEMBL5761451 0.75 KDM4E (0.33) ALDH1A1GABRA1GABRG2GABRB3GABRA5
SCHEMBL5759007 0.75 CHRM2 (0.36) ALDH1A1GABRA1GABRG2GABRB3GABRA5
SCHEMBL5757369 0.75 SYK (0.38) ALDH1A1GABRA1GABRG2GABRB3GABRA5
SCHEMBL5760823 0.73 GAA (0.39) ALDH1A1MAOBGABRA1GABRG2GABRB3
SCHEMBL7575843 0.73 MCHR1 (0.47) ALDH1A1RAB9AMAPTPKMKDM4E
SCHEMBL7583364 0.71 MCHR1 (0.48) ALDH1A1NPC1SMN1; SMN2RAB9AMAPT
SCHEMBL7580732 0.70 MCHR1 (0.49) ALDH1A1SLC6A3MAPTPKMCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1104403-B1 HYDROXY PIPECOLATE HYDROXAMIC ACID DERIVATIVES AS MMP INHIBITORS PFIZER PROD INC (US) 2006-05-10 EP disclosed
US-20050215549-A1 TACE inhibitors MCCLURE KIM F 2005-09-29 US disclosed
EP-1104412-B1 TACE INHIBITORS PFIZER PROD INC (US) 2005-06-15 EP disclosed
US-20030181441-A1 TACE INHIBITORS McCLURE Kim (US) 2003-09-25 US disclosed
US-6329397-B1 TREATMENT OF A CONDITION SELECTED FROM THE GROUP CONSISTING OF ARTHRITIS, CANCER, AND OTHER DISEASES CHARACTERIZED BY MATRIX METALLOPROTEINASE OR MAMMALIAN REPROLYSIN ACTIVITY. PFIZER 2001-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181441-A1 TACE INHIBITORS ADAMTS5, ADAMTS1, MMP2 ALDH1A1 2961/4885KDM1A 2887/4885MAOB 4221/4885
US-20050215549-A1 TACE inhibitors ADAMTS5, ADAMTS1, MMP2 ALDH1A1 2994/4885KDM1A 3146/4885MAOB 3725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.